《大行報告》野村上調百濟神州(06160.HK)目標價至186.87元 評級「買入」
野村發表報告指,百濟神州(06160.HK)首季銷售額繼續快速增長,淨虧損收窄,維持「買入」評級,目標價由172.81元升至186.87港元。
該行指,在Zanubrutinib和Tislelizuma銷售增長推動下,百濟神州首季收入按年增長46%至4.48億美元。
經營虧損亦按年收窄16.2%至3.71億美元,主要是由於研發費用比率降低至91.2%,以及營業費用比率降低至73.4%。因此淨虧損收窄至3.48億美元,按年減少19.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.